Browsing by Author "Ferhanoglu, Burhan"

Now showing 1 - 3 of 3

Brentuximab Vedotin And Bendamustine: An Effective Salvage Therapy For Relapsed Or Refractory Hodgkin Lymphoma Patients
(2022) Ulu, Bahar Uncu; Dal, Mehmet Sinan; Hindilerden, Ipek Yonal; Akay, Olga Meltem; Mehtap, Ozgur; Buyukkurt, Nurhilal; Hindilerden, Fehmi; Gunes, Ahmet Kursad; Yigenoglu, Tugce Nur; Basci, Semih; Cakar, Merih Kizil; Acik, Didar Yanardag; Korkmaz, Serdal; Ulas, Turgay; Ozet, Gulsum; Ferhanoglu, Burhan; Nalcaci, Meliha; Altuntas, Fevzi; https://orcid.org/0000-0002-0895-4787; 34514960; AAE-1457-2021
The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m(2) B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients' median age at BvB initiation was 33 (range: 18-76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2-11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.
Effectiveness of Bendamustine in Relapse or Refractory Lymphoma Cases: A Report From Turkey-The Turkish Oncology Group (TOG) Study.
(2017) Karadurmus, Nuri; Paydas, Semra; Ocal, Ramazan; Yildiz, Birol; Nayir, Erdinc; Dogan, Mutlu; Sumbul, Ahmet Taner; Surmeli, Zeki; Barista, Ibrahim; Ferhanoglu, Burhan; Ozgur, Gokhan; Erturk, Ismail; Ozaydin, Sukru; Petekkaya, Halil Ibrahim; Uskent, Necdet
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study
(2021) Karadurmus, Nuri; Paydas, Semra; Esin, Ece; Surmeli, Zeki Gokhan; Yildiz, Birol; Erturk, Ismail; Nayir, Erdinc; Dogan, Mutlu; Sumbul, Ahmet Taner; Barista, Ibrahim; Gurkan, Emel; Ocal, Ramazan; Ferhanoglu, Burhan; Ozgur, Gokhan; Karakas, Yusuf; Lacin, Sahin; Ozaydin, Sukru; Petekkaya, Halil İbrahim; Uskent, Necdet; 34336021
Introduction: We aimed to investigate the efficacy and side effects of bendamustine in relapsed/refractory lymphoma patients in Turkey. Material and methods: In this retrospective study, we included relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients who underwent multiple lines of chemotherapy. The primary endpoint was to determine the objective response and toxicity. Results: Ninety-nine patients with a median age of 59.8 years were included in the study. Eighty-one patients had NHL (follicular lymphoma: 10, diffuse large B- cell lymphoma: 27, mantle-cell lymphoma: 18, marginal zone lymphoma: 9, small lymphocytic lymphoma/chronic lymphocytic leukemia: 17) and 18 patients had HL. The patients had previously received a median of three lines of chemotherapy (range: 2-8) except autologous stem cell transplantation (ASCT); 19 patients (HL: 11, NHL: 8) had undergone ASCT. The objective response rate (ORR) was 74.3%, the complete response rate was 57% (= 53), and the partial response rate was 16.6% (= 19). The overall survival (OS) rate at 1 year was 74.6%. The progression-free survival (PFS) rate at 1 year was 62.5%. The most common side effects were lymphopenia, anemia and neutropenia. Side effects which were observed as grade 3 and higher levels were lymphopenia (14.1%), neutropenia (10.1%) and fatigue (7.1%). Conclusions: Objective response rate of bendamustine was found to be 74.3% in relapsed/refractory HL and NHL patients. It appears to be an effective option as a salvage treatment for patients who have previously received multiple lines of therapy.